The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Gilenya made revenues of $2.8 billion in 20021, with half of that total coming from the US market, although it has started to shrink as a result of increased competition in the market for ...

Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

Additionally, as the Sandoz spin-off was completed on October 2023, there were no operating results in 2024 related to discontinued operations.

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The Second U.S ...

A US court has ordered generic drug makers to stop selling a copy of Gilenya in US. The annual sales of Gilenya, a drug used to treat multiple sclerosis, was about $3.3 billion in 2018.